Long-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.

Start Date02 Apr 2024

Sponsor / Collaborator

Alzheon, Inc.

NCT04770220

/ CompletedPhase 3

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.

Start Date19 May 2021

Sponsor / Collaborator

Alzheon, Inc.

[+1]

NCT04693520

/ CompletedPhase 2

A Phase 2, Single-arm Study of the Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4)

The study will investigate the effects of oral ALZ-801, in subjects with Early AD who have the APOE4/4 or APOE3/4 genotype, on the biomarkers of core AD pathology. The objectives of this study include determining the efficacy and safety/tolerability of ALZ-801. In addition, the study will evaluate the extended PK profile over 8 hours in 16 subjects after 65 weeks of treatment.

Start Date30 Sep 2020

Sponsor / Collaborator

Alzheon, Inc.

100 Clinical Results associated with Valiltramiprosate

100 Translational Medicine associated with Valiltramiprosate

100 Patents (Medical) associated with Valiltramiprosate

Literatures (Medical) associated with Valiltramiprosate

01 Feb 2026·CNS DRUGS

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials

Review

Author: Porsteinsson, Anton ; Dickson, Sam ; Tosun, Duygu ; Hey, John A ; Yu, Jeremy ; Albayrak, Adem ; Flint, Susan ; Petrella, Jeffrey ; Kesslak, J Patrick ; Bracoud, Luc ; Doraiswamy, P Murali ; Durrant, Abe ; Ritchie, Craig ; McLaine, Rosalind ; McSweeney, Emer ; Schaefer, Jean F ; Tolar, Martin ; Sabbagh, Marwan ; Abushakra, Susan ; Gauthier, Serge ; Bray, Margaret ; Barakos, Jerome ; Barkhof, Frederik ; Liang, Earvin ; Hendrix, Suzanne ; Boada, Merce ; Watson, David ; Cohen, Sharon ; Power, Aidan

Amyloid-plaque reduction is currently the only recognized surrogate outcome for Alzheimer's disease (AD) trials, allowing accelerated approval of plaque-clearing amyloid antibodies. However, plaque reduction does not facilitate the development of new non-plaque-clearing treatments. The hippocampus is among the first brain regions affected by AD pathology, exhibiting synaptic dysfunction and neurodegeneration that manifests as hippocampal atrophy and memory decline. We evaluated hippocampal volume (HV) as a potential surrogate outcome that can predict clinical benefit in disease-modification trials. Using published data from observational and interventional studies that examined both cognition and HV on volumetric magnetic resonance imaging (vMRI), we evaluated the cross-sectional correlations of HV to cognitive performance, the longitudinal correlations of HV atrophy to cognitive decline, HV sensitivity to drug effects, and the correlations between drug effects on HV atrophy and cognitive decline. We also examined the magnitude of HV protection that corresponds to meaningful clinical benefit. Analyses from 30 observational studies encompassing 13,187 individuals (2633 cognitively normal; 10,554 early AD) showed significant cross-sectional correlations between baseline HV and cognition, and longitudinal correlations between HV atrophy and cognitive decline over ≥ 1 year. The relationship of HV-cognitive drug effects was examined at the group level in nine placebo-controlled trials of five antiamyloid agents that evaluated HV in early AD trials of at least 18 months' duration. These trials included four amyloid antibodies (aducanumab, lecanemab, donanemab, and gantenerumab) and one oral anti-oligomer agent (valiltramiprosate). Individual-level HV-cognition relationships were examined in two valiltramiprosate studies, one of which included diffusion tensor imaging (DTI) providing microstructural correlates of HV drug effects and helping distinguish neuroprotection from brain edema. Across these anti-amyloid drug trials (total N ~10,000), there was a linear relationship between drug effects on slowing of cognitive decline and slowing of HV atrophy. Two anti-oligomer trials (valiltramiprosate) reported significant subject-level correlations between drug effects on HV and cognition over 18-24 months (r = -0.40 to -0.44, p < 0.005, N = 50/69), with significant correlations of drug effects on brain microstructure (decreased mean diffusivity) with both HV and cognitive benefits, supporting reduced neurodegeneration. The minimal HV preservation at the mild cognitive impairment (MCI) stage that is associated with clinical benefit is estimated to be ≥ 40 mm³ or ≥ 10% of atrophy in the placebo arm over 18 months. Our findings demonstrate that hippocampal atrophy is an early indicator of cognitive decline in AD, linked to amyloid and tau-related neurodegeneration. HV on standardized vMRI is sensitive to anti-amyloid treatments, demonstrating strong correlations between slowed hippocampal atrophy and slowed cognitive decline. Data from over 23,000 subjects over three decades support HV as a surrogate marker for predicting clinical benefit in early symptomatic AD.

01 Jan 2026·INTERNAL MEDICINE

Therapeutic Potential of Oral ALZ-801 in Patients with Alzheimer's Disease

Article

Author: Noguchi-Shinohara, Moeko ; Ono, Kenjiro ; Muramatsu, Daiki

Alzheimer's disease (AD), the most common cause of dementia, is characterized by amyloid-β (Aβ) plaques in the brain. ALZ-801, a prodrug of tramiprosate, was developed as an oral disease-modifying therapy for patients with AD. Tramiprosate and ALZ-801 inhibit Aβ aggregation and reduce Aβ-induced cytotoxicity. Although the prespecified endpoints were not met in two Phase 3 trials involving tramiprosate, post hoc analyses indicated benefits in apolipoprotein E ε4 homozygotes. Furthermore, no cases of amyloid-related imaging abnormalities-edema/effusion were detected. In the APOLLOE4 Phase 3 study of ALZ-801 in apolipoprotein E ε4 homozygous patients with early AD, the primary endpoint was not achieved; however, the mild cognitive impairment subgroup demonstrated nominal efficacy. ALZ-801 has not been associated with amyloid-related imaging abnormalities, a major safety concern of anti-Aβ antibodies, and may represent a safe oral alternative to anti-Aβ antibody therapies.

01 Dec 2025·Alzheimers & Dementia

Safety and ARIA Results of the Oral Anti‐Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD

Article

Author: MacSweeney, Emer ; Abushakra, Susan ; Watson, David ; Barakos, Jerome ; Sabbagh, Marwan N. ; Flint, Susan ; Power, Aidan ; Boada, Mercè ; MacLaine, Rosalind ; Tolar, Martin ; Liang, Earvin ; Porsteinsson, Anton P. ; Cohen, Sharon ; Hey, John A. ; Kesslak, Patrick

Abstract:

Background:

Valiltramiprosate/ALZ‐801, an oral inhibitor of amyloid oligomer formation, was evaluated in a Phase 3 trial in APOE4/4 homozygotes with Early AD, with main results presented at this meeting (Power et al, 2025). APOE4 is a risk factor for cerebral amlyloid angiopathy (CAA) and ARIA. Tramiprosate (active agent in ALZ‐801) had shown no ARIA‐E in prior studies, allowing the APOLLOE4 trial to include subjects with any number of microhemorrhages (MH) and several siderosis lesions at screening MRI.

Method:

This 78‐week placebo‐controlled trial enrolled 325 homozygotes who received placebo or 265 mg BID. Anti‐coagulants were exclusionary. In addition to adverse event (AE) assessments, MRIs were performed every 26 weeks and evaluated by Clario Inc. for occurrence of ARIA with edema and/or microhemorrhage/siderosis (ARIA‐E, ARIA‐H).

Result:

Safety population ( N =325) was 51% females, 89% Caucasian, mean age 68 years, MMSE 25.6, with MCI vs. Mild AD (39% vs 61%); 298 had screening MRI (149/arm provided ≥1 post‐dose MRI). At baseline, 32% had >1 MH (placebo, 32%, active, 31%); 11% in placebo and 8% in active arm had siderosis (maximum 4 and 5 lesions, respectively); and 5% in each arm had ≥ 10 MH. New ARIA‐E occurred during the study in 5 subjects in each arm (3%) and new macrohemorrhages in 2 subjects/arm. Increase in MH from low to high category (0, 1‐4, 5‐9, ≥10 MH) was seen in 14% placebo and 9% active arm. Radiographic ARIA were all mild except 1 severe (placebo) and 1 moderate (active); all were without symptoms. AEs with incidence >5% and >2x placebo rate were nausea (26%), weight decrease (14%), decreased appetite and vomiting (10% each); with lower incidence of headache, falls and dizziness in active arm.

Conclusion:

APOLLOE4 enrolled homozygotes with a high CAA burden who would be ineligibile for amyloid antibody treatments. Valiltramiprosate overall safety was favorable and consistent with prior studies. ARIA‐E incidence was similar to placebo, and ARIA‐H was lower than placebo with no symptomatic ARIA events over 78 weeks of treatment. Coupled with promising efficacy in MCI subjects, valiltramiprosate can provide a favorable benefit‐risk profile for the high‐risk APOE4/4 patients with unmet treatment need.

News (Medical) associated with Valiltramiprosate

14 Apr 2026

·www.biospace.com

Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer’s Patients Leading to Reduced Brain Edema and Microhemorrhage Risk at 2026 American Academy of Neurology Meeting in Chicago, Illinois

Valiltramiprosate Shows Favorable Safety Outcomes with Low ARIA Risk and Evidence of Neurovascular Protection in APOE4/4 Alzheimer’s Patients Precision Medicine Approach Supported by Phase 3 and Phase 2 Results in High-Risk APOE4/4 Patients with Mild Cognitive Impairment (MCI) Presentations Highlight Consistent Effects of Valiltramiprosate on Clinical Outcomes, Brain Volume Preservation, and Long-Term Disease Stability in MCI Valiltramiprosate Targets Toxic Amyloid Oligomers Upstream of Antibodies, Offering Potential Disease Modification Without Increased Risk of Vascular Injury FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801 -- Alzheon, Inc. , a clinical-stage biopharmaceutical company developing investigational therapies for patients with Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced it will present new clinical, safety, imaging, and biomarker findings, as well as brain edema (ARIA-E) and brain microhemorrhage (ARIA-H) for its lead investigational therapy, valiltramiprosate/ALZ-801, at the American Academy of Neurology (AAN) Annual Meeting in Chicago, Illinois. "Valiltramiprosate is currently the only remaining oral candidate with promise to improve patient outcomes in the foreseeable future. In our studies, valiltramiprosate demonstrates a distinct profile, as an oral anti-amyloid therapy with potential to slow disease progression while maintaining vascular integrity in early-stage Alzheimer's patients APOE4/4 patients, who are particularly susceptible to brain edema and microhemorrhage complications associated with anti-amyloid antibodies," stated Susan Abushakra, MD, Chief Medical Officer at Alzheon. "The data presented at AAN will outline the reduced incidence and delayed onset of ARIA-H observed in the Phase 3 study involving 298 APOE4/4 AD subjects, alongside brain volume benefits that show significant correlations with clinical outcomes within the pre-specified MCI subgroup. These findings, together with supportive results from the four-year Phase 2 study, showcase the potential of valiltramiprosate to provide clinically meaningful benefits without elevating ARIA risk and while decreasing microvascular injury." In the Phase 3 study, valiltramiprosate showed favorable safety and neurovascular results over 78 weeks, with low and balanced ARIA-E incidence (3% in both treatment and placebo arms). Across all ARIA subtypes, the active arm showed consistent reductions in the incidence of new events. In the placebo arm, 29% of subjects had new ARIA-H or ARIA-E vs. 19% in active arm, a significant 35% reduction (p=0.031). In addition, there was a delay to onset of new ARIA-H or ARIA-E events in the active arm (p<0.02). Incidence of concurrent microhemorrhages and siderosis was reduced by 89% (p=0.01) and their onset was delayed by 41% (p=0.02) in the active arm. Across both Phase 3 and Phase 2 studies, all ARIA-E and ARIA-H events were asymptomatic. “The consistency we are seeing between clinical outcomes and brain volume preservation is particularly compelling,” said Marwan N. Sabbagh, MD, FAAN. “These correlations suggest that targeting amyloid oligomers upstream of amyloid antibodies may meaningfully impact the underlying biology of the disease and slow brain neurodegeneration. The favorable and differentiated safety results, especially the low ARIA-E risk in APOE4/4 patients with reduced incidence of ARIA-H, further supports valiltramiprosate as a promising and differentiated oral treatment for early-stage Alzheimer’s disease.” These findings suggest that valiltramiprosate may provide protective effects on cerebral microvasculature through reduction of vascular amyloid burden and/or by inhibiting inflammatory responses. This is particularly relevant in APOE4/4 patients, who have high prevalence of cerebral amyloid angiopathy with exaggerated inflammatory responses, leading to heightened risk of ARIA. The observed neurovascular effects in the overall Phase 3 study population are also consistent with findings from diffusion tensor imaging, showing significant preservation of microstructural integrity in white matter tracts that connect the hippocampus to cortical areas including the default mode network, as well as significantly reduced ventricular expansion and whole brain atrophy. Details of Presentations at AAN Annual Meeting Oral Presentation: Sunday, April 19, 2026 Session: New Perspectives on Alzheimer’s Therapeutics Safety and ARIA Analyses of Oral Anti-amyloid Oligomer Agent Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Results of the Phase 3 78-week APOLLOE4 Trial Presenter: Susan Abushakra, Chief Medical Officer, Alzheon, Inc. Lecture Time: 2:36 PM – 2:48 PM CDT Poster Presentations: Sunday, April 19, 2026 Time: 8:00 AM – 9:00 AM CDT Effects of Oral Valiltramiprosate on Clinical Efficacy, Safety, and Brain Volume Outcomes in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Topline Results of the 78-week Phase 3 APOLLOE4 Trial Presenter: Susan Abushakra, MD, Chief Medical Officer, Alzheon, Inc. Monday, April 20, 2026 Time: 8:00 AM – 9:00 AM CDT Biomarker-positive APOE4 Carriers with MCI Show Cognitive Stability over 4 Years of Oral Valiltramiprosate/ALZ-801 Treatment: MMSE Responder Analysis from the ALZ-801 Phase 2 Long-term Extension Study Presenter: Patrick Kesslak, PhD, Senior Research Fellow, Alzheon, Inc. Monday, April 20, 2026 Time: 5:00 PM – 6:00 PM CDT Clinical Effects of Oral Valiltramiprosate Treatment in APOE4 Carriers with Mild Cognitive Impairment (MCI): Results of the Phase 2 Study Long-term Extension over 3 Years Presenter: Susan Abushakra, MD, Chief Medical Officer, Alzheon, Inc. Correlations between Clinical and Brain Volume Effects of Oral Valiltramiprosate in APOE4/4 Homozygotes with MCI: Pre-specified Analyses of the Phase-3 APOLLOE4 78-Week Trial Presenter: Marwan N. Sabbagh, MD, FAAN About ALZ-801 Valiltramiprosate/ALZ-801 is an investigational oral agent currently in Phase 3 development as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease. 3-7,9,12 Valiltramiprosate is designed to inhibit the formation of neurotoxic soluble beta amyloid oligomers that contribute to cognitive decline in individuals with AD. 4-8,10,15 Preclinical mechanism-of-action studies have demonstrated that ALZ-801 can completely block the formation of these neurotoxic oligomers at the dosage used in Phase 3 clinical trials. 3,9,12,14 Valiltramiprosate employs an enveloping molecular mechanism of action intended to prevent the aggregation of soluble amyloid oligomers in the human brain, 14 which are associated with the onset and progression of cognitive impairment in AD patients. 3,4,7,9,10 In recognition of its therapeutic promise, valiltramiprosate received Fast Track designation from the U.S. Food and Drug Administration in 2017 for the treatment of Alzheimer’s disease. Clinical trial data indicate that valiltramiprosate exhibits strong clinical efficacy at the MCI stage, and a favorable safety profile, with no observed increase in the risk of brain vasogenic edema. 1-10,13,15 The initial Phase 3 program for valiltramiprosate targets Early AD patients who are homozygous for the apolipoprotein ε4 allele (APOE4/4), with plans to expand future research to include AD treatment and prevention in individuals carrying one copy of the APOE4 gene. 3–10 Valiltramiprosate APOLLOE4 Phase 3 Trial An Efficacy and Safety Study of Valiltramiprosate in APOE4/4 Early Alzheimer's Disease Subjects ( NCT04770220 ): This trial was designed to evaluate the efficacy, safety, biomarker and imaging effects of 265 mg twice daily oral dose of valiltramiprosate in Early AD subjects with two copies of the apolipoprotein ε4 allele (APOE4/4 homozygotes), who constitute approximately 15% of Alzheimer's patients. This double-blind, randomized trial compared oral valiltramiprosate to placebo treatment over 78 weeks. The APOLLOE4 trial was supported by a grant from the National Institute on Aging to Alzheon, with Susan Abushakra as the principal investigator. Valiltramiprosate APOLLOE4 Long Term Extension Trial (Phase 3 LTE) A long-term extension of the trial, APOLLOE4-LTE, evaluated valiltramiprosate in subjects who complete the core APOLLOE4 study for an additional 104 weeks of treatment for a total of 182 weeks or 3.5 years over the core and LTE study. This LTE study ended in January 2026 ( NCT06304883 ). Valiltramiprosate Phase 2 Biomarker Trial Biomarker Effects of Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease ( NCT04693520 ): This trial was designed to evaluate the effects of 265 mg twice daily oral dose of valiltramiprosate on biomarkers of AD pathology in subjects with Early AD, who have either the APOE4/4 or APOE3/4 genotype and constitute 65-70% of Alzheimer's patients. The primary outcome was the change from baseline in plasma p-tau 181 . The trial also included evaluation of clinical efficacy, safety, tolerability, and pharmacokinetic pro valiltramiprosate over 104 weeks of treatment. A completed long-term extension of the trial evaluated the same dose of valiltramiprosate for an additional 104 weeks of treatment for a total of 208 weeks. 3,7,8 About Alzheon Alzheon, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a diverse portfolio of product candidates and diagnostic assays for individuals affected by Alzheimer’s disease and other neurodegenerative disorders. The company is focused on innovating therapeutic solutions that directly target the underlying pathology of neurodegeneration. Its lead Alzheimer's clinical candidate, valiltramiprosate/ALZ-801 , is a first-in-class oral agent currently in Phase 3 clinical development as a potentially disease-modifying treatment for Alzheimer’s disease. Valiltramiprosate is an orally administered small molecule shown in preclinical studies to completely inhibit the formation of neurotoxic soluble amyloid oligomers. Its well-differentiated follow-on candidate, ALZ-507, is a once daily oral therapy designed to inhibit the formation of amyloid oligomers while also correcting the high risk APOE4 gene. Leveraging clinical expertise and a robust technology platform, Alzheon pursues drug discovery and development using a precision medicine approach that incorporates individual genetic and biomarker pro aiming to advance therapies with meaningful benefits for patients. Alzheon Scientific Publications 1 Abushakra S, et al: Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials, CNS Drugs 2026; 40, 199-214. 2 Abushakra S, et al: Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial , Drugs 2025; 85, 1455-1472. 3 Pearson D, et al: Polymorph Analysis of ALZ-801 (Valiltramiprosate), a Valine-Conjugated Oral Prodrug of Tramiprosate in Late-Stage Clinical Development for Alzheimer’s Disease, Journal of Chemical Crystallography 2025; 55, 206-215. 4 Hey JA, et al: Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a Two-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease, Clinical Pharmacokinetics 2025; 64, 407-424. 5 Aye S, et al: Point of View: Challenges in Implementation of New Immunotherapies for Alzheimer’s Disease, The Journal of Prevention of Alzheimer’s Disease 2025;12(1):100022. 6 Abushakra S, et al: APOLLOE4 Phase 3 Study of Oral ALZ-801/Valiltramiprosate in APOE ε 4/ ε 4 Homozygotes with Early Alzheimer’s Disease: Trial Design and Baseline Characteristics, Alzheimer’s & Dementia 2024; 10(3): e12498. 7 Tolar M, et al: The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention, International Journal of Molecular Sciences 2024; 25(5), 2727. 8 Hey JA, et al: Analysis of Cerebrospinal Fluid, Plasma β Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model, Drugs 2024; 84(7), 825-839. 9 Hey JA, et al: Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single Arm, Open Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease, Drugs 2024; 84(7), 811-823. 10 Tolar M, et al: Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression , International Journal of Molecular Sciences 2021; 22(12), 6355. 11 Abushakra S, et al: APOE ε4/ε4 Homozygotes with Early Alzheimer’s Disease Show Accelerated Hippocampal Atrophy and Cortical Thinning that Correlates with Cognitive Decline , Alzheimer’s & Dementia 2020; 6(1): e12117. 12 Tolar M, et al: Aducanumab, Gantenerumab, BAN2401, and ALZ-801—the First Wave of Amyloid-Targeting Drugs for Alzheimer’s Disease with Potential for Near Term Approval, Alzheimer’s Research & Therapy 2020; 12(1): 95. 13 Tolar M, et al: The Path Forward in Alzheimer’s Disease Therapeutics: Reevaluating the Amyloid Cascade Hypothesis , Alzheimer’s & Dementia 2020; 16(11):1553-1560. 14 Hey JA, et al: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain , CNS Drugs 2018; 32(9): 849-861. 15 Hey JA, et al: Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease , Clinical Pharmacokinetics 2018; 57(3): 315-333. 16 Abushakra S, et al: Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential , Journal of Prevention of Alzheimer’s Disease 2017; 4(3): 149-156. 17 Kocis P, et al: Elucidating the A β 42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods , Pharmacokinetic and Clinical Data , CNS Drugs 2017; 31(6): 495-509. 18 Abushakra S, et al: Clinical Benefits of Tramiprosate in Alzheimer’s Disease Are Associated with Higher Number of APOE4 Alleles: The “APOE4 Gene-Dose Effect,” Journal of Prevention of Alzheimer’s Disease 2016; 3(4): 219-228. Contacts Media Contact Yasemin Khakian, Alzheon, Inc. 508.808.2301 yasemin.khakian@alzheon.com Investor Contact Erwan de Naurois, Alzheon, Inc. 802.735.8789 erwan.denaurois@alzheon.com

Phase 2Clinical ResultPhase 3Fast Track

07 Apr 2026

·www.biospace.com

Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism

ALZ-507 Designed as Well-Differentiated Oral Candidate Targeting Soluble Amyloid Oligomer Pathology, with Additional Mechanism of Action as APOE4 Corrector ALZ-507 IND Program Demonstrated Favorable Nonclinical Safety and Pharmacokinetic Pro Supports Once-Daily Dosing ALZ-507 Broadens Alzheon’s Proprietary Precision Medicine Therapeutic Pipeline Targeting Disease Modification in Alzheimer’s Disease FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801 -- Alzheon, Inc. , a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the dosing of the first cohort of human volunteer subjects in a Phase 1 single and multiple ascending dose clinical trial of ALZ-507, a novel investigational oral drug candidate for the treatment of Alzheimer’s disease. Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon, commented: “Dosing the first subject with ALZ-507 marks years of scientific progress at Alzheon as we deepen our understanding of Alzheimer’s disease biology. This well-differentiated next-generation Alzheimer’s drug candidate also functions as an APOE4 corrector, strengthening its anti-oligomer properties. ALZ-507 is a major step forward for Alzheon’s precision medicine platform aimed at the prevention of formation of neurotoxic soluble amyloid oligomers. With Alzheimer’s disease still representing a critical global unmet medical need, we are committed to work toward bringing to patients novel, safe, and accessible therapies that have the potential to slow disease progression.” ALZ-507 is an orally administered small molecule developed to target upstream amyloid aggregation and inhibit the formation of neurotoxic soluble amyloid oligomers, which are recognized as a key trigger and driver of Alzheimer’s disease pathology. Additionally, ALZ-507 features an APOE4 corrector mechanism of action, potentially augmenting its primary anti-oligomer pharmacological effects. Designed as a next-generation oral treatment for Alzheimer's disease, ALZ-507 may offer the advantages of once-daily dosing and improved gastrointestinal tolerability. The Phase 1 study, employing an oral capsule formulation, will assess the safety, tolerability, and pharmacokinetics in healthy volunteer participants. “The initiation of the ALZ-507 Phase 1 study with our novel oral product candidate demonstrates the capability of our development platform and our methodical approach to progressing high-quality, disease-modifying oral therapies with optimized pharmaceutical properties,” stated John Hey, PhD, Chief Scientific Officer at Alzheon. “Building on our experience with upstream inhibition of amyloid aggregation, ALZ-507 further expands our portfolio of oral treatments designed to target the main causes of neurodegeneration. Preclinical studies have shown evidence of a positive safety and pharmacokinetic profile, as well as an enhanced efficacy profile, making ALZ-507 a valuable addition to Alzheon’s portfolio of potential disease-modifying treatments for Alzheimer's disease.” The Phase 1 clinical trial will assess the safety, tolerability, and pharmacokinetics of both single and multiple ascending doses of ALZ-507. Findings from this investigation are anticipated to guide dose selection and inform formulation strategy for subsequent Phase 2 studies involving patients diagnosed with Alzheimer’s disease (AD), Down syndrome–associated AD, and cerebral amyloid angiopathy (CAA). About ALZ-801 Valiltramiprosate/ALZ-801 is an investigational oral agent currently in Phase 3 development as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease. 3-7,9,12 Valiltramiprosate is designed to inhibit the formation of neurotoxic soluble beta amyloid oligomers that contribute to cognitive decline in individuals with AD. 4-8,10,15 Preclinical mechanism-of-action studies have demonstrated that ALZ-801 can completely block the formation of these neurotoxic oligomers at the dosage used in Phase 3 clinical trials. 3,9,12,14 Valiltramiprosate employs an enveloping molecular mechanism of action intended to prevent the aggregation of soluble amyloid oligomers in the human brain, 14 which are associated with the onset and progression of cognitive impairment in AD patients. 3,4,7,9,10 In recognition of its therapeutic promise, valiltramiprosate received Fast Track designation from the U.S. Food and Drug Administration in 2017 for the treatment of Alzheimer’s disease. Clinical trial data indicate that valiltramiprosate exhibits strong clinical efficacy at the MCI stage, and a favorable safety profile, with no observed increase in the risk of brain vasogenic edema. 1-10,13,15 The initial Phase 3 program for valiltramiprosate targets Early AD patients who are homozygous for the apolipoprotein ε4 allele (APOE4/4), with plans to expand future research to include AD treatment and prevention in individuals carrying one copy of the APOE4 gene. 3–10 Valiltramiprosate APOLLOE4 Phase 3 Trial An Efficacy and Safety Study of Valiltramiprosate in APOE4/4 Early Alzheimer's Disease Subjects ( NCT04770220 ): This trial was designed to evaluate the efficacy, safety, biomarker and imaging effects of 265 mg twice daily oral dose of valiltramiprosate in Early AD subjects with two copies of the apolipoprotein ε4 allele (APOE4/4 homozygotes), who constitute approximately 15% of Alzheimer's patients. This double-blind, randomized trial compared oral valiltramiprosate to placebo treatment over 78 weeks. The APOLLOE4 trial was supported by a grant from the National Institute on Aging to Alzheon, with Susan Abushakra as the principal investigator. Valiltramiprosate APOLLOE4 Long Term Extension Trial (Phase 3 LTE) A long-term extension of the trial, APOLLOE4-LTE, evaluated valiltramiprosate in subjects who complete the core APOLLOE4 study for an additional 104 weeks of treatment for a total of 182 weeks or 3.5 years over the core and LTE study. This LTE study ended in January 2026 ( NCT06304883 ). Valiltramiprosate Phase 2 Biomarker Trial Biomarker Effects of Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease ( NCT04693520 ): This trial was designed to evaluate the effects of 265 mg twice daily oral dose of valiltramiprosate on biomarkers of AD pathology in subjects with Early AD, who have either the APOE4/4 or APOE3/4 genotype and constitute 65-70% of Alzheimer's patients. The primary outcome was the change from baseline in plasma p-tau 181 . The trial also included evaluation of clinical efficacy, safety, tolerability, and pharmacokinetic pro valiltramiprosate over 104 weeks of treatment. A completed long-term extension of the trial evaluated the same dose of valiltramiprosate for an additional 104 weeks of treatment for a total of 208 weeks. 3,7,8 About Alzheon Alzheon, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a diverse portfolio of product candidates and diagnostic assays for individuals affected by Alzheimer’s disease and other neurodegenerative disorders. The company is focused on innovating therapeutic solutions that directly target the underlying pathology of neurodegeneration. Its lead Alzheimer's clinical candidate, valiltramiprosate/ALZ-801 , is a first-in-class oral agent currently in Phase 3 clinical development as a potentially disease-modifying treatment for Alzheimer’s disease. Valiltramiprosate is an orally administered small molecule shown in preclinical studies to completely inhibit the formation of neurotoxic soluble amyloid oligomers. Its well-differentiated follow-on candidate, ALZ-507, is a once daily oral therapy designed to inhibit the formation of amyloid oligomers while also correcting the high risk APOE4 gene. Leveraging clinical expertise and a robust technology platform, Alzheon pursues drug discovery and development using a precision medicine approach that incorporates individual genetic and biomarker pro aiming to advance therapies with meaningful benefits for patients. Alzheon Scientific Publications 1 Abushakra S, et al: Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials, CNS Drugs 2026; 40, 199-214. 2 Abushakra S, et al: Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial , Drugs 2025; 85, 1455-1472. 3 Pearson D, et al: Polymorph Analysis of ALZ-801 (Valiltramiprosate), a Valine-Conjugated Oral Prodrug of Tramiprosate in Late-Stage Clinical Development for Alzheimer’s Disease, Journal of Chemical Crystallography 2025; 55, 206-215. 4 Hey JA, et al: Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a Two-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease, Clinical Pharmacokinetics 2025; 64, 407-424. 5 Aye S, et al: Point of View: Challenges in Implementation of New Immunotherapies for Alzheimer’s Disease, The Journal of Prevention of Alzheimer’s Disease 2025;12(1):100022. 6 Abushakra S, et al: APOLLOE4 Phase 3 Study of Oral ALZ-801/Valiltramiprosate in APOE ε 4/ ε 4 Homozygotes with Early Alzheimer’s Disease: Trial Design and Baseline Characteristics, Alzheimer’s & Dementia 2024; 10(3): e12498. 7 Tolar M, et al: The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention, International Journal of Molecular Sciences 2024; 25(5), 2727. 8 Hey JA, et al: Analysis of Cerebrospinal Fluid, Plasma β Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model, Drugs 2024; 84(7), 825-839. 9 Hey JA, et al: Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single Arm, Open Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease, Drugs 2024; 84(7), 811-823. 10 Tolar M, et al: Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression , International Journal of Molecular Sciences 2021; 22(12), 6355. 11 Abushakra S, et al: APOE ε4/ε4 Homozygotes with Early Alzheimer’s Disease Show Accelerated Hippocampal Atrophy and Cortical Thinning that Correlates with Cognitive Decline , Alzheimer’s & Dementia 2020; 6(1): e12117. 12 Tolar M, et al: Aducanumab, Gantenerumab, BAN2401, and ALZ-801—the First Wave of Amyloid-Targeting Drugs for Alzheimer’s Disease with Potential for Near Term Approval, Alzheimer’s Research & Therapy 2020; 12(1): 95. 13 Tolar M, et al: The Path Forward in Alzheimer’s Disease Therapeutics: Reevaluating the Amyloid Cascade Hypothesis , Alzheimer’s & Dementia 2020; 16(11):1553-1560. 14 Hey JA, et al: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain , CNS Drugs 2018; 32(9): 849-861. 15 Hey JA, et al: Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease , Clinical Pharmacokinetics 2018; 57(3): 315-333. 16 Abushakra S, et al: Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential , Journal of Prevention of Alzheimer’s Disease 2017; 4(3): 149-156. 17 Kocis P, et al: Elucidating the A β 42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods , Pharmacokinetic and Clinical Data , CNS Drugs 2017; 31(6): 495-509. 18 Abushakra S, et al: Clinical Benefits of Tramiprosate in Alzheimer’s Disease Are Associated with Higher Number of APOE4 Alleles: The “APOE4 Gene-Dose Effect, ” Journal of Prevention of Alzheimer’s Disease 2016; 3(4): 219-228. Contacts Media Contact Yasemin Khakian, Alzheon, Inc. 508.808.2301 yasemin.khakian@alzheon.com Investor Contact Erwan de Naurois, Alzheon, Inc. 802.735.8789 erwan.denaurois@alzheon.com

Phase 3Phase 2Phase 1Clinical ResultFast Track

27 Mar 2026

·www.biospace.com

Eisai, Alzheon Drill Down on Promising Results in High-Risk Alzheimer’s Subset

iStock, Nomadsoul1 At the AD/PD annual meeting, Eisai presented real-world data suggesting Leqembi’s long-term safety and efficacy in people homozygous for APOE4 , who were identified in trials as being at higher risk of brain bleeds while on the treatment. Alzheon, meanwhile, added further detail to trial results of its candidate in patients with the same genetic profile. Carrying two copies of the gene variant APOE ɛ4 has long been linked to an increased risk of developing Alzheimer’s disease. Cruelly, the same genetic pro associated with brain bleed events known as ARIA-H and ARIA-E in trials of Biogen and Eisai’s Leqembi, and some regulators, including the European Medicines Agency, have carved out APOE ɛ4 homozygotes as ineligible for the groundbreaking anti-amyloid therapy. Armed with real-world data, Eisai made a case earlier this month at the AD/PD annual meeting in Copenhagen that most of these treatment-associated bleeds in people with two copies of APOE4 (defined as homozygous) were not as common as in earlier trial data, and that the risk dropped off after six months of treatment. Moreover, most people did not experience disease progression over the course of the study. Meanwhile, Alzheon, which rolled out topline results at the same meeting last year showing that its candidate, valiltramiprosate, missed its primary endpoint in a Phase 3 trial that enrolled people homozygous for APOE4 , was back this year with more details on that study as well as a new data from a Phase 2 trial. Alzheon presented biomarker and brain imaging data to bolster positive results on a cognitive assessment for patients who enrolled in the study with mild cognitive impairment (MCI) rather than later in the course of the disease. “The conference had a significant focus on biomarkers, and there [have] been such tremendous advances that these biomarkers are really allowing us to understand the underlying biology of the patients that we’re trying to treat with therapies,” Aaron Burstein, head of search and evaluation at the Alzheimer’s Drug Discovery Foundation, told BioSpace . Eisai’s data was “very encouraging” and “provides additional support for the potential use of these agents in the APOE4 carrier status as was approved by FDA,” he said. As for Alzheon’s results, Burstein said the biomarker data “provided support that the hypothesized clinical benefits they were seeing were associated with measures consistent with actually having effects on the underlying biological processes.” Genes and Brain Bleeds Approved by the FDA in July 2023, Leqembi carries a black-box warning noting that APOE4 homozygotes have a higher risk of amyloid-related imaging abnormalities (ARIA) when treated with this class of medication and recommending that providers genetically test patients before prescribing it. “Consider the benefit for the treatment of Alzheimer’s disease and risk of ARIA when deciding to treat with LEQEMBI.,” the warning states. An analysis of the Phase 3 trial results found that people homozygous for APOE4 had a 45% chance of developing ARIA-E when taking Leqembi, compared with 13% for noncarriers and 19% for patients heterozygous for the variant. This is thought to be because APOE4 is associated with a greater buildup of amyloid proteins near the blood vessel walls, and when that buildup is removed, “sometimes there’s this leakage that occurs,” explained Lynn Kramer, Eisai’s chief clinical officer. In the real-world analysis, which included the records of 207 patients at sites across the U.S., the increased risk was less stark than in the trial: 21.2% of APOE4 homozygotes developed ARIA, versus 13.7% of noncarriers. All but one of the cases in each group were asymptomatic. On the benefits side of the equation, 76% of people with two copies of APOE4 were at the same or an improved disease stage at the final follow-up compared to when they began treatment. On average, patients were followed for 491 days. Kramer noted that relative to the pivotal trial, homozygous patients in the real-world analysis were, on average, enrolled at a later disease stage. “Our thinking is they should be treated earlier like everybody else if you want to get maximum benefit,” he told BioSpace . “But I think this type of information makes physicians maybe more comfortable in understanding the risks so that they start treating the patients a little sooner.” In addition, he said, the company intends to continue collecting real-world data in hopes of eventually getting labels changed in countries that don’t include APOE4 -homozygous patients in their drug authorizations. In an extension of Leqembi’s Phase 3 trial, Eisai has seen the difference in disease stage between treated people and matched external controls widen over time, Kramer added. And “after the first six months or so, these ARIA events just occur at the same frequency as they would in the [external control] group. . . . So the risk is really at the beginning. . . . That’s why the benefit improvement is important.” Toward a Precision Approach The fact that Alzheon focused on APOE4 carriers in its own trials is no accident. Under its original sponsor, NeuroChem, tramiprosate did not have statistically significant effects in patients with Alzheimer’s in a clinical trial and was put on ice. But posthoc analysis indicated the modified amino acid had benefited participants homozygous for APOE4 , said John Hey, chief scientific officer at Alzheon. The startup licensed the drug from NeuroChem and is developing a prodrug version, valiltramiprosate, specifically in that population. Apart from the drug’s biological effects, an additional reason for focusing on APOE4 homozygotes first, Hey said, is their higher unmet need due to restrictions and warnings around Leqembi’s use. Among the new results presented at AD/PD, Burstein singled out those showing a sustained reduction in levels of p-tau-217, a biomarker associated with amyloid pathology, as particularly interesting. Patients with MCI in the Phase 2 study have shown a drop in levels of the biomarker compared with baseline that has lasted through four years of follow-up, according to Hey’s presentation. That reduction correlated with clinical measures. Speaking with BioSpace , Hey highlighted the safety results of the Phase 3 study, which found no difference in ARIA-E rates for the drug versus placebo. For ARIA-H, rates were actually lower in the treatment group. Valiltramiprosate acts to block the formation of toxic aggregates in the brain, and “if you prevent that neurotoxic wave in the neurodegeneration and the sequelae of events that lead to the inflammatory milieu that leads to ARIA . . . you get a benefit on neurovascular outcomes,” Hey suggested. The next steps for Alzheon, he said, will be to conduct confirmatory studies in APOE4 homozygous and heterozygous patients with MCI. Ultimately, he sees the drug being used for patients when they first begin to show symptoms—or even before—in order to glean maximum benefit from treatment. “I think as we see the advent of the fluid biomarkers, those will be used increasingly for diagnostic and for precision treatment to give some tools for the physician on how to treat these subjects,” Hey said.

Clinical ResultPhase 3Phase 2Drug Approval

100 Deals associated with Valiltramiprosate

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	United States	Alzheon, Inc.	19 May 2021
Alzheimer Disease	Phase 3	Canada	Alzheon, Inc.	19 May 2021
Alzheimer Disease	Phase 3	Czechia	Alzheon, Inc.	19 May 2021
Alzheimer Disease	Phase 3	France	Alzheon, Inc.	19 May 2021
Alzheimer Disease	Phase 3	Germany	Alzheon, Inc.	19 May 2021
Alzheimer Disease	Phase 3	Iceland	Alzheon, Inc.	19 May 2021
Alzheimer Disease	Phase 3	Netherlands	Alzheon, Inc.	19 May 2021
Alzheimer Disease	Phase 3	Spain	Alzheon, Inc.	19 May 2021
Alzheimer Disease	Phase 3	United Kingdom	Alzheon, Inc.	19 May 2021
Down Syndrome	Clinical	United States	Alzheon, Inc.	11 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04770220 (APOLLOE4, AAN 12026 \| AAN 22026 \| AAN 32026 \| AAN 42026 \| AAN 52026 \| AAN 62026 \| AAN 72026)	Phase 3	Alzheimer Disease APOE4/4	325	Valiltramiprosate 265 mg BID	tfyhpizppw(cfdupqdgeu) = nrbnnrrpys fdckljcgzo (typhundoaq ) View more	Positive	25 Apr 2026
				placebo	-
NCT04770220 (APOLLOE4, CTgov)	Phase 3	Alzheimer Disease	325	Placebo Comparator: Placebo (Placebo)	lcboiqkmkv(oyqobgogum) = vpiovtfhly fxnuziqqui (umptjheddo, 0.69) View more	-	10 Nov 2025
				Placebo Comparator: Placebo+Experimental: ALZ-801 (ALZ-801)	lcboiqkmkv(oyqobgogum) = csssosqopq fxnuziqqui (umptjheddo, 0.69) View more
NCT04770220 (APOLLOE4, Pubmed \| Drugs)	Phase 3	Alzheimer Disease	325	Valiltramiprosate	iwmftzjcga(xgrwwyyjzg): P-Value = 0.607 View more	Positive	01 Nov 2025
				Placebo
NCT04770220 (Company_Website) Manual	Phase 3	Alzheimer Disease APOE4/4 homozygotes	325	valiltramiprosate	sjvdonygjn(nkemlpnxir): Difference (LS Mean) = -0.504, P-Value = 0.607 Not Met View more	Negative	10 Apr 2025
				Placebo
AAIC2024	Phase 2	Alzheimer Disease Aβ42 \| p-tau181	70	ALZ-801 265 mg BID	lumokqcyaf(pkbukgvrqb) = uqpdldvsio bhlpdsjoza (cemtpkxmmj )	Positive	28 Jul 2024
NCT04693520 (phase 2, Pubmed \| Drugs)	Phase 2	Alzheimer Disease plasma Aβ42	84	ALZ-801 265 mg tablet	ioxutaaveb(uqdczooyqe) = bvixzavjej ifclacthhx (gqcnrwkzap )	Positive	01 Jul 2024
NCT04693520 (Biospace) Manual	Phase 2	Alzheimer Disease	84	ALZ-801/Valiltramiprosate 265 mg	zxjwkvxdcb(pabdewfsct) = statistically significant and clinically relevant reduction in plasma biomarkers of neurodegeneration, preservation of brain volume, and positive cognitive effects in Early AD patients who are carriers of apolipoprotein ε4 allele (APOE4) following 24 months of treatment with investigational oral agent ALZ-801/valiltramiprosate. ydbpdjqaeh (balxtazsws )	Positive	25 Jun 2024
NCT04770220 (APOLLOE4, CTAD2023)	Phase 3	Alzheimer Disease APOE4/4	325	ALZ-801	iybclujbea(gdgtupbwus) = yerqhzlbzs gksyspnmfh (rzgkplsgkq ) View more	Positive	24 Oct 2023
				ALZ-801 (CAA subgroup)	iybclujbea(gdgtupbwus) = gptaspzlor gksyspnmfh (rzgkplsgkq ) View more
CTAD2023	Phase 2	Alzheimer Disease p-tau181 \| Aβ42 \| Aβ40	84	ALZ-801 265 mg BID	emntguciml(qublliulyd) = no ARIA-E to date xcmpcmrdyc (qlcuvpzzbb ) View more	Positive	24 Oct 2023
NCT04693520 (Corporate Publications) Manual	Phase 2	Alzheimer Disease	75	Valiltramiprosate	cuvivqwgdr(enfnfmnejp) = edafhcgogr uumrgghxyz (ddmnjgfpfh ) View more	Positive	20 Sep 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Valiltramiprosate

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation